Top Page
Shanghai Haohai Biological Technology Co., Ltd. Class H
(6826)
Shanghai Haohai Biological Technology Co., Ltd. Class H (6826) vs. iShares MSCI Hong Kong ETF (EWH)
Shanghai Haohai Biological Technology Co., Ltd. Class H Business Overview & Revenue Model
Shanghai Haohai Biological Technology Co., Ltd. Class H Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.67B | 2.68B | 2.63B | 2.10B | 1.75B | 1.32B |
| Gross Profit | 1.47B | 1.87B | 1.85B | 1.45B | 1.26B | 990.42M |
| EBITDA | 643.57M | 665.04M | 713.41M | 447.55M | 550.45M | 394.80M |
| Net Income | 412.92M | 420.45M | 416.12M | 180.47M | 352.23M | 230.07M |
Balance Sheet | ||||||
| Total Assets | 7.13B | 7.12B | 7.11B | 6.89B | 6.95B | 6.30B |
| Cash, Cash Equivalents and Short-Term Investments | 2.66B | 2.76B | 2.75B | 2.54B | 2.91B | 3.11B |
| Total Debt | 452.51M | 448.43M | 407.95M | 118.26M | 105.51M | 108.08M |
| Total Liabilities | 1.18B | 1.20B | 1.09B | 990.02M | 890.07M | 564.46M |
| Stockholders Equity | 5.67B | 5.58B | 5.65B | 5.51B | 5.71B | 5.49B |
Cash Flow | ||||||
| Free Cash Flow | 254.80M | 283.08M | 367.22M | -85.85M | 70.19M | 66.21M |
| Operating Cash Flow | 440.55M | 648.57M | 634.45M | 231.30M | 342.29M | 262.07M |
| Investing Cash Flow | -183.48M | 282.28M | -376.65M | -681.82M | -148.09M | 316.92M |
| Financing Cash Flow | -511.56M | -390.35M | -257.73M | -288.35M | -231.25M | -190.06M |
Shanghai Haohai Biological Technology Co., Ltd. Class H Technical Analysis
Shanghai Haohai Biological Technology Co., Ltd. Class H Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | HK$11.75B | 12.85 | 7.25% | 4.43% | -1.81% | -3.79% | |
62 Neutral | HK$8.99B | 245.40 | 4.16% | ― | 34.39% | ― | |
54 Neutral | HK$12.99B | ― | -18.87% | ― | 16.35% | -49.63% | |
53 Neutral | HK$8.35B | ― | -13.97% | ― | -97.81% | -117.20% | |
53 Neutral | HK$13.30B | ― | -55.68% | ― | ― | -4.33% | |
51 Neutral | $7.41B | 0.36 | -61.88% | 2.33% | 17.09% | 1.64% | |
49 Neutral | HK$9.84B | ― | -51.40% | ― | 58.75% | -1310.16% |
Shanghai Haohai Biological Technology Co., Ltd. Class H Corporate Events
Shanghai Haohai Biological Technology Co., Ltd. has announced the composition of its board of directors, highlighting the roles and functions of each member. The board consists of executive, non-executive, and independent non-executive directors, with various members serving on four key committees: Audit, Remuneration and Review, Nomination, and Strategy and Sustainable Development. This announcement underscores the company’s commitment to structured governance and strategic oversight, potentially impacting its operational efficiency and stakeholder confidence.
Shanghai Haohai Biological Technology Co., Ltd. has established an audit committee to enhance its corporate governance and financial oversight. The committee is responsible for reviewing financial information, supervising audits, and ensuring effective management oversight, which is expected to strengthen the company’s decision-making and governance structure.
Shanghai Haohai Biological Technology Co., Ltd. has established a remuneration and appraisal committee under its Board of Directors to enhance its remuneration management system. This committee is responsible for setting performance evaluation indicators and remuneration systems for directors and senior management, ensuring a formal and transparent process for developing remuneration policies, and making recommendations on remuneration packages. The move aims to align the company’s governance with regulatory requirements and improve oversight of executive compensation, potentially impacting its market positioning and stakeholder confidence.
Shanghai Haohai Biological Technology Co., Ltd. has established a Nomination Committee under its Board of Directors to enhance corporate governance. This committee is responsible for setting criteria and procedures for selecting directors and senior management, ensuring the board’s composition aligns with the company’s strategic goals, and maintaining board diversity. This move aims to optimize board operations and improve decision-making processes, which could strengthen the company’s industry positioning and stakeholder confidence.
Shanghai Haohai Biological Technology Co., Ltd. successfully held its Annual General Meeting and class meetings for A and H shareholders, where all proposed resolutions were approved. Significant decisions included the 2024 profit distribution, election of a new board session, and the abolishment of the supervisory committee, which are expected to impact the company’s governance and operational strategies.
Shanghai Haohai Biological Technology Co., Ltd. has announced a final cash dividend of RMB 0.6 per share for the financial year ending December 31, 2024, with the payment date set for July 18, 2025. The dividend will be paid in Hong Kong dollars at an exchange rate of RMB 1 to HKD 1.091715, and the withholding tax rates will vary depending on the residency status of the shareholders, impacting non-resident and resident shareholders differently.
Shanghai Haohai Biological Technology Co., Ltd. has announced key changes in its board and management structure. Dr. Hou Yongtai has been re-elected as Chairman, and Mr. Wu Jianying continues as General Manager, with Ms. Tian Min re-elected as Secretary to the Board and Securities Affairs Representative. These appointments, effective immediately, are part of the company’s strategic efforts to strengthen its governance and operational leadership.
Shanghai Haohai Biological Technology Co., Ltd. has announced proposed amendments to its Articles of Association, which include abolishing the supervisory committee and transferring its responsibilities to the audit committee. These changes align with recent regulatory updates in China and Hong Kong, aiming to streamline governance structures and incorporate electronic voting and hybrid shareholder meetings. The amendments are subject to shareholder approval at the upcoming annual general meeting.
Shanghai Haohai Biological Technology Co., Ltd. has announced an update regarding its final cash dividend for the year ending December 31, 2024. The dividend is set at RMB 0.6 per share, with shareholders’ approval scheduled for June 10, 2025. The announcement includes details about the Hong Kong share register, ex-dividend date, and withholding tax rates applicable to different types of shareholders. This update is significant for stakeholders as it outlines the financial returns and tax implications for investors, reflecting the company’s financial health and commitment to shareholder value.
Shanghai Haohai Biological Technology Co., Ltd. has announced its 2024 Annual General Meeting scheduled for June 10, 2025, where key resolutions will be considered, including the approval of the 2024 Annual Report, remuneration plans, and profit distribution. A significant proposal includes the abolishment of the Supervisory Committee and amendments to the Articles of Association and procedural rules, alongside granting the Board a mandate to repurchase H Shares, which could impact the company’s governance and shareholder value.
Shanghai Haohai Biological Technology Co., Ltd. has announced a 2025 first H shareholders’ class meeting scheduled for June 10, 2025, following their 2024 annual general meeting. During this meeting, a special resolution will be considered to grant the Board a general mandate to repurchase up to 10% of the H Shares in issue. This move is aimed at optimizing the company’s capital structure and enhancing shareholder value, reflecting strategic positioning in the market.
Shanghai Haohai Biological Technology Co., Ltd. has announced the election of a new board session as the current board’s term is nearing its end. The new board will consist of eleven directors, including a mix of executive, non-executive, and independent non-executive directors. The proposals for re-election are subject to shareholder approval at the upcoming annual general meeting. Additionally, Mr. Zhao Lei, an independent non-executive director, will retire and not seek re-election due to personal reasons. The company has expressed gratitude for Mr. Zhao’s contributions during his tenure.
Shanghai Haohai Biological Technology Co., Ltd. announced that one of its controlling shareholders, Mr. Jiang Wei, has been notified by the China Securities Regulatory Commission (CSRC) regarding a case filing for suspected insider trading. The company clarified that this investigation is personal to Mr. Jiang Wei and does not involve the company’s shares or affect its daily operations. The company will continue to monitor the situation and fulfill its disclosure obligations.
Shanghai Haohai Biological Technology Co., Ltd. announced amendments to its Articles of Association following the repurchase and cancellation of 2,296,200 H shares, which reduced the company’s total share count and registered capital. These changes reflect the company’s strategic decision to adjust its capital structure, potentially impacting its market positioning and shareholder value. The amendments, effective April 25, 2025, will not require further approval at the general meeting, indicating a streamlined internal decision-making process.
Shanghai Haohai Biological Technology Co., Ltd. reported a slight decline in revenue and net profit for the first quarter of 2025 compared to the same period last year. Despite a decrease in R&D expenses, the company experienced a positive increase in net cash flows from operating activities, indicating a potential improvement in operational efficiency.
Shanghai Haohai Biological Technology Co., Ltd. has announced that its board of directors will meet on April 25, 2025, to review and approve the company’s first quarterly results for the period ending March 31, 2025. This meeting is significant as it will provide insights into the company’s financial performance and strategic direction, potentially impacting its market positioning and stakeholder interests.